Skip to content

Metabolic Risk Assessment in Prepubertal Children With Congenital Hypothyroidism

Metabolic Risk Assessment in Prepubertal Children With Congenital Hypothyroidism (IpoMet)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07126353
Acronym
IpoMet
Enrollment
170
Registered
2025-08-17
Start date
2025-09-30
Completion date
2026-10-31
Last updated
2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Hypothyroidism, Metabolic Syndrome

Keywords

Congenital hypothyroidism, metabolic syndrome, Obesity

Brief summary

We propose a multicenter prospective study to define the prevalence and severity score of metabolic syndrome in a prepubertal pediatric cohort with congenital hypothyroidism, compared to a healthy and normal-weight pediatric population. These data will help to define whether hypothyroidism can be considered a risk factor for the metabolic health of the pediatric population. The possible identification of an at-risk metabolic profile will provide useful information to optimize the diagnostic and monitoring pathway for affected children.

Detailed description

Primary congenital hypothyroidism is the most common endocrine disorder in childhood and can present in either a permanent or transient form. Prolonged thyroid hormone deficiency can cause widespread damage affecting multiple organs and systems. Exposure to thyroid hormone deficiency during fetal and/or neonatal life has particularly severe consequences on the central nervous system, leading to neurocognitive delay. Appropriate and timely hormone replacement therapy (L-thyroxine) can prevent such outcomes, provided it is initiated early. Thyroid hormones play a crucial role not only in growth and organ development but also in metabolic homeostasis. Thyroid function lies at the crossroads of multiple metabolic pathways. They have multiple effects on glucose and lipid metabolism, specifically by increasing glucose levels, fatty acid oxidation in muscle and liver, and lipolysis in adipose tissue. They also contribute to blood pressure regulation, thereby influencing the prevalence of metabolic syndrome, which is itself a key predictor of type 2 diabetes, cardiovascular diseases, and neurodegenerative conditions.Thyroid function plays a central regulatory role at the intersection of key metabolic pathways. Although, the role of thyroid hormones in metabolic processes is well established, and a bidirectional relationship between metabolic dysfunction and thyroid hypofunction has been reported in the adult population, data on metabolic risk in pediatric patients with congenital hypothyroidism are currently lacking. The primary aim of this multicenter project is to assess the prevalence of metabolic syndrome in patients with congenital hypothyroidism and to determine whether this population presents a higher metabolic risk profile compared to the general population. As secondary objectives, this prospective study aims to: 1. Define the prevalence and severity score of metabolic syndrome in a prepubertal pediatric cohort with congenital hypothyroidism, compared to a pediatric population with obesity. 2. Evaluate the correlations between individual metabolic dysfunction parameters and the clinical and hormonal profile (including thyroid hormone levels and thyroid hormone sensitivity indices). 3. Assess the correlations between the metabolic profile and renal function. 4. Assess the correlations between the hormonal profile and renal function. To achieve these objectives, auxological parameters, vital signs (including blood pressure and heart rate), and metabolic profile data (glucose and lipid profiles, renal function, and hormonal status - FT3, FT4, TSH and thyroid hormone resistence indices TSHI, TT4RI, TT3RI, TFQI, PTFQI) will be collected for each enrolled subject. These parameters will be evaluated on peripheral blood samples collected during routine blood monitoring already scheduled according to established follow up. The potential presence of metabolic syndrome will be evaluated in each enrolled patient. The severity of the metabolic disorder will be evaluated using the Metabolic Score (MetS). Data analysis will be performed using the statistical packages R 4.0.5 (R Core Team, 2021) and STATA (version 15.1, 2017, Stata Corporation, College Station, Texas, USA).

Interventions

OTHERprospective observational study (clinical, hormonal and auxological data)

We collect clinical, hormonal and auxological data and compare them between the two groups.

Sponsors

Federico II University
CollaboratorOTHER
IRCCS Ospedale San Raffaele
CollaboratorOTHER
Policlinico di Bari Giovanni XXIII
CollaboratorUNKNOWN
Azienda Ospedaliero Universitaria Policlinico Modena
CollaboratorOTHER
Azienda Ospedaliero-Universitaria di Parma
CollaboratorOTHER
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
CollaboratorOTHER
Azienda Ospedaliera Sant'Anna
CollaboratorOTHER
University Hospital Perugia
CollaboratorUNKNOWN
University of L'Aquila
CollaboratorOTHER
Clinica Pediatrica Università di Novara
CollaboratorUNKNOWN
Santobono-Pausilpon Hospital
CollaboratorUNKNOWN
Policlinico G . Martino, Messina Italy
CollaboratorUNKNOWN
IRCCS Azienda Ospedaliero-Universitaria di Bologna
CollaboratorOTHER
University Hospital of Ancona
CollaboratorUNKNOWN
Buzzi Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Pubertal stage Tanner 1 * Permanent congenital hypothyroidism * All ethnic groups * Informed consent signature

Exclusion criteria

* Age\< 5 years * Pubertal stage Tanner 2-5 * Transient congenital hypothyroidism or other type of hypothyroidism

Design outcomes

Primary

MeasureTime frameDescription
Metabolic syndrome (MS)At the time of enrollmentPresence of at least 3 of the following parameters: 1. BMI z-score ≥ 2 and/or waist-to-height ratio (WHtR) \> 0.5 2. Fasting blood glucose ≥ 100 mg/dL and/or TryG index ≥ 7.88 3. Total cholesterol ≥ 200 mg/dL 4. HDL cholesterol \< 40 mg/dL and/or LDL cholesterol ≥ 130 mg/dL 5. Triglycerides (TG) ≥ 100 mg/dL for ages 0-9 years; ≥ 130 mg/dL for ages \>10 years 6. Systolic and/or diastolic blood pressure (SBP and/or DBP) ≥ 90th percentile for age and sex
Metabolic score (MeTs)At the time of enrollmentMales MetS z-score = -4.931 + 0.2804 \* BMI z-score - 0.0257 \* HDL + 0.0189 \* SBP + 0.6240 \* log(triglycerides) + 0.0140 \* fasting glucose Females MetS z-score = -4.3757 + 0.4849 \* BMI z-score - 0.0176 \* HDL-C + 0.0257 \* SBP + 0.3172 \* log(triglycerides) + 0.0083 \* fasting glucose

Countries

Italy

Contacts

Primary ContactValeria Calcaterra, MD
valeria.calcaterra@unipv.it+39 0263631

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026